Velpatasvir/sofosbuvir: Difference between revisions
Anypodetos (talk | contribs) Link kinetics, interactions |
Anypodetos (talk | contribs) →top: Per Template talk:Infobox drug#Identifiers in boxes for drug combination – hope I did this right (kinetic data also aren't useful for drug combinations) |
||
| Line 17: | Line 17: | ||
| legal_US = Rx-only |
| legal_US = Rx-only |
||
| pregnancy_US = B |
| pregnancy_US = B |
||
<!--Pharmacokinetic data--> |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| elimination_half-life = |
|||
| excretion = |
|||
<!--Identifiers--> |
<!--Identifiers--> |
||
| ⚫ | |||
| QID=Q25110523<!-- v. --> |
|||
| QID2=Q25110523<!-- s. --> |
|||
| index_comment = velpatasvir |
|||
| index2_comment = sofosbuvir |
|||
| index_label = v. |
|||
| index2_label = s. |
|||
| ⚫ | |||
| CAS_number2 = 1190307-88-0 |
|||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = |
| PubChem = 91885554 |
||
| |
| KEGG = D10827 |
||
| DrugBank = |
|||
| UNII = KCU0C7RS7Z |
|||
| UNII2 = WJ6CA3ZU8B |
|||
| KEGG2 = D10366 |
|||
| ChEBI = 133009 |
|||
| ChEBI2 = 85083 |
|||
| ChEMBL2 = 1259059 |
|||
| ChemSpiderID = 34501056 |
|||
| ChemSpiderID2 = 26286922 |
|||
}} |
}} |
||
Revision as of 15:50, 23 February 2017
| Combination of | |
|---|---|
| Velpatasvir | NS5A inhibitor |
| Sofosbuvir | NS5B (RNA polymerase) inhibitor |
| Clinical data | |
| Trade names | Epclusa |
| AHFS/Drugs.com | epclusa |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| KEGG | |
Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase. A single tablet regimen is used for adults with genotype 1–6 chronic hepatitis C virus (HCV) infection.[1]
Velpatasvir/sofosbuvir was developed by the pharmaceutical company Gilead Sciences and approved by US FDA in June 2016.[2] In the European Union it was approved on 6 July 2016 for the treatment of chronic hepatitis C virus infection in adults.[3]
Contraindications
Combining velpatasvir/sofosbuvir with strong inducers of the liver enzymes CYP2B6, CYP2C8 or CYP3A4, or with P-glycoprotein, is contraindicated because such substances may reduce the effectiveness of the hepatitis C drug.[4]
Side effects
Common side effects (in more than 10% of people) are headache, fatigue and nausea. In studies, severe side effects were experienced in 3% of patients, and 0.2% terminated the therapy because of adverse events. These effects occurred with similar frequencies in people treated with placebo.[4]
Interactions
Pharmacokinetics
History
Beacon Pharmaceuticals, Bangladesh, introduced a generic version product under the trade name of Sofosvel. Beacon got approval from the Directorate of Drug Administration, Ministry of Health and Family Welfare, People's Republic of Bangladesh.[5] Other Indian companies with similar licenses are expected to follow.[6]
References
- ^ FDA Approves Epclusa, Drugs.com
- ^ "FDA approves Epclusa for treatment of chronic Hepatitis C virus infection". Retrieved 14 July 2016.
- ^ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004210/human_med_001997.jsp&mid=WC0b01ac058001d124
- ^ a b Haberfeld, H, ed. (2016). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- ^ US’ Gilead faces competition from Bangladesh’s Beacon pharma, The Economic Times
- ^ http://esofosbuvir.com/sofosvel-generic-hepatitis-c-medicine-genotypes/